Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 4/20 | 0.53 |
| ▸ | CSF1R | P07333 | 4/20 | 0.53 |
| ▸ | ABL1 | P00519 | 5/20 | 0.53 |
| ▸ | KIT | P10721 | 6/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703596 | 0.86 | MAPK1 (0.59) | ABL1EGFRMAPK14MAPTHCK | |
| SCHEMBL1705288 | 0.81 | MAPK14 (0.57) | MAPK14NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL10159643 | 0.80 | TRPV1 (0.48) | LCKABL1KITKDRMAPK14 | |
| SCHEMBL1704606 | 0.78 | ABL1 (0.49) | CSF1RABL1MAPK14NPC1RAB9A | |
| SCHEMBL1705324 | 0.78 | ABL1 (0.43) | ABL1KITMAPK14NPC1RAB9A | |
| SCHEMBL10158099 | 0.76 | ABL1 (0.58) | ABL1KITKDRMAPK14MAPT | |
| SCHEMBL1704882 | 0.76 | MAPK14 (0.68) | LCKCSF1RKDRMAPK14BRAF | |
| SCHEMBL1705565 | 0.75 | LCK (0.65) | DDR2LCKCSF1RABL1KIT | |
| SCHEMBL31620769 | 0.75 | ABL1 (0.70) | DDR2LCKCSF1RABL1KIT | |
| SCHEMBL1696213 | 0.74 | LDHA (0.41) | LCKMAPK14NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | DDR2 4672/4885LCK 1107/4885CSF1R 4045/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | DDR2 3558/4885LCK 290/4885CSF1R 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.